Brain scanning technology to be used for clinical psychedelics trials in pioneering London start-up partnership

● British start-up Clerkenwell Health, Europe’s first commercial psychedelic clinical trials facility, and brain wellness and analytics company MYndspan, are partnering to advance the application of psychedelics in medicine ● Psychedelics researchers running trials at Clerkenwell Health’s new London site will have access to MYndspan’s non-invasive brain scanning technology ● This first-of-its-kind…


The product has been added to your cart.

Continue shopping View Cart